Mukerjee C M, McKenzie D K
Aust N Z J Med. 1985 Apr;15(2):226-9. doi: 10.1111/j.1445-5994.1985.tb04013.x.
The incidence and types of adverse reactions to rifampicin (in combination with isoniazid, pyrazinamide, and ethambutol) have been studied in 86 South-East Asian refugees treated for tuberculosis in Australia. Most patients received daily therapy initially (mean 3.5 months) followed by supervised thrice-weekly treatment (mean 4.6 months). Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required. Withdrawal of pyrazinamide was necessary in two patients (2.3%) with clinical hepatitis.
在澳大利亚，对86名接受利福平（联合异烟肼、吡嗪酰胺和乙胺丁醇）治疗结核病的东南亚难民，研究了其不良反应的发生率和类型。大多数患者最初接受每日治疗（平均3.5个月），随后接受监督下的每周三次治疗（平均4.6个月）。每日治疗（5%）和间歇治疗（5%）期间出现轻微不良反应的频率相似，但在任何情况下都无需调整利福平剂量。两名出现临床肝炎的患者（2.3%）需要停用吡嗪酰胺。
